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T cell dysfunction is well documented during chronic
viral infections but little is known about functional
abnormalities in humoral immunity. Here we report
that mice persistently infected with lymphocytic
choriomeningitis virus (LCMV) exhibit a severe defect
in Fcg-receptor (FcgR)-mediated antibody effector
functions. Using transgenic mice expressing human
CD20, we found that chronic LCMV infection im-
paired the depletion of B cells with rituximab, an
anti-CD20 antibody widely used for the treatment
of B cell lymphomas. In addition, FcgR-dependent
activation of dendritic cells by agonistic anti-CD40
antibody was compromised in chronically infected
mice. These defects were due to viral antigen-anti-
body complexes and not the chronic infection per
se, because FcgR-mediated effector functions were
normal in persistently infected mice that lacked
LCMV-specific antibodies. Our findings have impli-
cations for the therapeutic use of antibodies and
suggest that high levels of pre-existing immune
complexes could limit the effectiveness of antibody
therapy in humans.
INTRODUCTION
Antibodies are a key component of the immune systemproviding
long-term protective immunity against many pathogens and
regulating immune responses. Antibodies consist of two do-
mains with distinct functions. Whereas the variable Fab domain
mediates antigen specificity and binds its respective antigen,
the Fc domain mediates diverse effector functions via recruit-
ment of effector molecules such as complement and Fc recep-
tors (FcRs). Although the Fc domain of immunoglobulin G (IgG)
is considered to be an invariable region, it displays marked het-
erogeneity due to different subclasses with divergent amino acidsequences, as well as complex glycosylation patterns (Pincetic
et al., 2014). This heterogeneity has been shown to modulate
the effector function of IgG by altering the binding to activating
and inhibitory FcgRs, thus triggering different pathways (Kaneko
et al., 2006; Shields et al., 2002).
Besides complement, FcgRs, which are expressed by most
hematopoietic cells, represent the main effector molecules re-
cruited by IgG (Nimmerjahn and Ravetch, 2008). Upon antigen
encounter, antibodies form immune complexes (ICs) with their
cognate antigen and bind to FcgRs. The uptake of ICs by acti-
vating FcgRs on dendritic cells (DCs) has shown to result in
cell maturation and efficient presentation of antigen on MHC-I
and MHC-II molecules (Kalergis and Ravetch, 2002; Regnault
et al., 1999). FcgRs on follicular DCs in the germinal center can
retain ICs and contribute to the affinity maturation of B
cells (Barrington et al., 2002). Furthermore, Fc-FcgR interactions
also play an important role in the protective capacity of neutral-
izing antibodies against various pathogens and toxins in vivo
(Abboud et al., 2010; DiLillo et al., 2014; Halper-Stromberg
et al., 2014; Hessell et al., 2007). Natural killer (NK) cells have
been shown to contribute to the FcgR-dependent protective
capacity of neutralizing antibodies against influenza and HIV
by antibody-dependent cellular cytotoxicity (ADCC) (DiLillo
et al., 2014; Hessell et al., 2007). In addition, it is well established
that macrophages contribute to pathogen clearance by anti-
body-dependent phagocytosis in a number of infectious dis-
eases (Kirimanjeswara et al., 2005; Zhang et al., 2005).
The mechanism of action of many therapeutic antibodies crit-
ically relies on Fc-FcgR interactions. Rituximab, a chimeric
monoclonal antibody (mAb) directed against CD20, is widely
used for treatment of non-Hodgkin’s lymphoma and autoim-
mune diseases (Browning, 2006; Cheson and Leonard, 2008;
Edwards et al., 2004). The engagement of activating FcgRs on
effector cells, such asmacrophages and NK cells, results in anti-
body-dependent phagocytosis or ADCC of opsonized B cells,
which have been shown to be the major mechanisms of action
of rituximab in vivo (Gong et al., 2005; Uchida et al., 2004). Tras-
tuzumab, amAb directed against the epidermal growth factor re-
ceptor HER2-neu on breast cancer cells, also depends on FcgR
interactions as FcgR polymorphisms in human FcgRIIIa haveImmunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc. 367
shown to affect clinical efficacy (Musolino et al., 2008; Varchetta
et al., 2007). Additional anticancer antibodies for which the
engagement of activating FcgRs on effector cells has shown to
mediate clinical efficacy comprise alemtuzumab, an anti-CD52
mAb used for treatment of B cell chronic lymphocytic leukemia,
and cetuximab, an anti-HER1 mAb against metastatic colorectal
cancer, metastatic non-small-cell lung cancer, and head and
neck cancer (Hu et al., 2009; Yang et al., 2013). Bavituximab, a
mAb directed against phosphatidylserine, which is translocated
to the outer leaflet on the plasma membrane by malignant trans-
formation or many viral infections, seems to mainly act via ADCC
and is currently undergoing clinical trials (Soares et al., 2008).
Furthermore, inhibitory FcgRs have been shown to play a crucial
role for the in vivo activity of agonistic anti-CD40 antibodies to
promote immune activation and anti-tumor immunity (Li and
Ravetch, 2011, 2013).
In this study, we initially wanted to investigate the role of virus-
specific CD4+T cells during an established chronic lymphocytic
choriomeningitis virus (LCMV) infection by depleting CD4+
T cells with a widely used anti-CD4 antibody. Surprisingly,
CD4+ T cells in chronically LCMV infectedmicewere highly resis-
tant to antibody-mediated depletion. While T cell dysfunction
and the underlying molecular mechanisms during chronic infec-
tions such as LCMV have been extensively studied, little is
known about defects in humoral immunity. We thus investigated
the mechanisms underlying this unexpected resistance to anti-
body-mediated depletion. We show that chronic LCMV infection
results in excessive IC formation and thereby interferes with anti-
body effector functions by competition for available FcgRs.
Chronic LCMV infection severely impairs antibody-mediated
depletion of various lymphocyte subsets as well as the activation
of dendritic cells by a FcgR-dependent agonistic anti-CD40
antibody. These findings have important implications for the
treatment of autoimmune diseases and cancer and infectious
diseases with antibodies relying on the engagement of FcgRs.
In addition, such defects in antibody-mediated effector functions
could contribute to viral persistence.
RESULTS
Antibody-Mediated Depletion of CD4+ T Cells Is
Impaired during Chronic LCMV Infection
To determine the role of virus-specific CD4+ T cells during an es-
tablished chronic LCMV clone-13 infection, we treated LCMV
clone-13-infected mice with a depleting anti-CD4 antibody
(GK1.5), which has been extensively used in various studies
(Jing et al., 2009; Matloubian et al., 1994). We injected C57BL/
6 mice chronically infected with LCMV (4 weeks post infection)
and age-matched naive controls on two consecutive days with
0.5 mg of anti-CD4 antibody intraperitoneally (i.p.). As expected,
treatment of naive mice resulted in efficient depletion of CD4+
T cells from the peripheral blood (>98%) within 2 days, interest-
ingly, CD4+ T cells of LCMV clone-13-infected mice seemed to
be resistant to depletion showing a significantly reduced deple-
tion efficiency (<10%) (Figures 1A and 1B). Similar results were
obtained when we analyzed the total number of CD4+ T cells in
the spleen of treated mice compared to untreated controls (Fig-
ures 1C and 1D). CD4+ T cells in the spleen of naive controls
showed a high susceptibility to depletion (>92%) compared to368 Immunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc.almost undetectable changes in the number of CD4+ T cells in
LCMV clone-13 infected animals (<10%).
The observed resistance of CD4+ T cells in LCMV clone-13-in-
fectedmice to depletion was not due to reduced surface expres-
sion of CD4 as CD4+ T cells from chronically infected mice
expressed comparable amounts as depletion-susceptible naive
controls (Figure 1E). Increased expression of CD47, a ubiqui-
tously expressed trans-membrane protein, on lymphomas was
shown to facilitate evasion from phagocytosis by interacting
with the inhibitory receptor SIRPa on macrophages (Jaiswal
et al., 2009; Majeti et al., 2009). We thus examined whether
the observed resistance of CD4+ T cells to antibody-mediated
depletion during chronic LCMV clone-13 infection was caused
by increased expression of CD47. However, we did not detect
any significant differences in CD47 expression between CD4+
T cells of naive and chronically LCMV clone-13-infected mice
(Figure 1F). These data thus suggest that the observed resis-
tance of CD4+ T cells to antibody-mediated depletion is either
CD4+ T cell-intrinsic due to unknown mechanisms or based on
defects in the depleting effector population.
CD4+ T Cells of LCMV InfectedMice Are Not Intrinsically
Resistant to Antibody-Mediated Depletion
To determine whether unknown target cell-intrinsic mecha-
nisms or cell-extrinsic factors were responsible for the
observed resistance to antibody-mediated depletion during
LCMV clone-13 infection, we performed an in vivo depletion
assay modified from our previous study (Barber et al., 2003).
Splenic CD4+ T cells from C57BL/6 mice 4 weeks after infec-
tion with either LCMV clone-13 (chronic infection) or LCMV
Arm (acute infection cleared by day 8), or from uninfected,
age-matched controls, were differentially labeled with CFSE
and CellTrace Violet and coated with anti-CD4 or left untreated.
These cells were then co-transferred into uninfected age-
matched, LCMV Arm immune, and chronically LCMV clone-
13-infected mice (Figure 2A). Co-transfer of anti-CD4 coated
and uncoated CD4+ T cells from donors differing in their infec-
tious history allowed us to directly address the contribution of
cell-intrinsic mechanisms to depletion resistance, whereas the
transfer of cells into hosts differing in their infectious history al-
lowed us to assess the role of cell-extrinsic factors. Anti-CD4
coated CD4+ T cells from naive, LCMV Arm immune and chron-
ically LCMV clone-13-infected mice were efficiently depleted
upon transfer into naı¨ve, as well as LCMV Arm immune, mice.
In contrast, chronically LCMV clone-13-infected mice failed to
efficiently deplete antibody-coated CD4+ T cells irrespective
of the donors’ infectious history (Figure 2B). The depletion of
antibody-coated CD4+ T cells in chronically LCMV clone-13-in-
fected mice was reduced compared to naive or LCMV Arm im-
mune mice, whereas no differences were observed between
naive and LCMV Arm immune mice (Figure 2C). These data
show that the striking resistance to antibody-mediated deple-
tion is specific to chronic LCMV clone-13 infection. In addition,
we did not observe differences in the depletion efficiency of
target cells isolated from donor mice with different infectious
history. Thus, the extent of antigen exposure and/or activation
status of the target cells did not influence their susceptibility to
depletion. In summary, these data demonstrate that cell-
extrinsic but not cell-intrinsic factors are causing the observed
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Figure 1. Antibody-Mediated Depletion of
CD4+ T Cells Is Severely Impaired in Chron-
ically LCMV Clone-13-Infected Mice
(A–F) Naive and LCMV clone-13-infected C57BL/6
mice (d28 p.i.) were injected twicewith 0.5mg anti-
CD4 depleting antibody. CD4+ depletion in the
peripheral blood and spleen was analyzed 2 days
after treatment start. (A) Representative flow plots
showing the frequency of CD4+ T cells as per-
centage of PBMC. (B) CD4+ depletion efficiency in
PBMC. (C) Representative flow plots showing the
frequency of CD4+ T cells as percentage of sple-
nocytes. (D) CD4+ depletion efficiency in spleen.
The surface expression of (E) CD4 and (F) CD47 on
CD4+ T cells prior treatment start were analyzed by
flow cytometry. Data (mean ± SEM) from one
representative experiment of more than 5 (n = 3–4
mice per group) are shown. Unpaired two-tailed
Student’s t test was used. *p < 0.05, ***p% 0.001.
ns indicates not significant. See also Figure S1.failure of antibody-mediated depletion of CD4+ T cells during
chronic LCMV clone-13 infection.
Macrophages of Naive and Chronically LCMV-Infected
Mice Show Comparable Phagocytic Activity In Vitro
Antibody-mediated depletion in vivo acts mainly through
engagement of FcgRs and subsequent phagocytosis of anti-
body-coated target cells by macrophages (Gong et al., 2005;
Uchida et al., 2004). We confirmed that phagocytosis is the
main effector mechanism mediating the depletion of CD4+
T cells by the anti-CD4 antibody used in this study. Depletion
of phagocytic cells using clodronate liposomes prevented anti-
body-mediated depletion of CD4+ T cells, whereas the deple-Immunity 42, 367–378,tion of NK cells using anti-NK1.1 anti-
body had no effect on the depletion
activity of anti-CD4 (Figure 3A, Figures
S1A and S1B). As LCMV clone-13 prefer-
entially infects macrophages and DCs,
resulting in virus-induced immunosup-
pression (Matloubian et al., 1993; Sevilla
et al., 2000), we hypothesized that
LCMV clone-13 infection might impair
macrophage-mediated phagocytosis of
antibody-coated target cells resulting
in the observed resistance to depletion.
Interestingly, binding/phagocytosis of
fluorescent microspheres by macro-
phages and DCs in vivo was not impaired
in LCMV clone-13-infected mice, sug-
gesting a defect specific to FcgR-medi-
ated phagocytosis (Figure S1C). Direct
ex vivo analysis of various phagocytic
subsets in the spleen showed slightly
elevated expression of FcgRII/III on
monocytes and neutrophils as well as of
FcgRIV on monocytes of LCMV clone-
13-infected mice compared to naive con-
trols (Figure S2). We thus compared the
phagocytic activity of monocytes/macro-phages from naive and chronically LCMV clone-13-infected
mice in vitro using a previously described FcgR-dependent
phagocytosis assay (Shashidharamurthy et al., 2008). We iso-
lated CD11b+ splenocytes and thioglycollate-induced perito-
neal exudate cells (PECs) from naive and chronically infected
mice. CD11b+ splenocytes of naive and LCMV clone-13-in-
fected mice showed comparable phagocytic activity in vitro,
which was dependent on the engagement of FcgRs (Figure 3B).
PECs obtained from chronically infected mice showed slightly
enhanced FcgR-mediated phagocytic activity in vitro compared
to naive controls (Figure 3C). Together, these experiments
using phagocytic cells derived from two different anatomical
sites demonstrate that chronic LCMV clone-13 infection doesFebruary 17, 2015 ª2015 Elsevier Inc. 369
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Figure 2. CD4+ T Cells of Chronically Infected Mice Are Not Intrinsically Resistant to Antibody-Mediated Depletion
(A–C) Anti-CD4 coated and uncoated CD4+ T cells of naive and LCMV clone-13/Arm-infected (d28 p.i.) mice were differentially fluorescently labeled, mixed to
equal proportions and transferred to naive and LCMV clone-13/Arm infected (d28 p.i.) mice. (A) Representative flow plot of transferred cell populations. (B)
Representative histograms are gated on fluorescently labeled CD3+ splenocytes of the indicated donor origin obtained 3 hr post transfer. Numbers indicate the
percentages of anti-CD4 coated and uncoated cells. (C) Depletion efficiency of anti-CD4 coated CD4+ T cells in naive and LCMV clone-13/Arm infected (d28 p.i.)
hosts within 3 hr post transfer. Data (mean ± SEM) from one representative experiment of two (n = 3–5 mice per group) are shown. A two-way ANOVA was used.
***p% 0.001.not impair FcgR-dependent phagocytosis in macrophages
in vitro suggesting a target, as well as effector cell-extrinsic
mechanism.
Excessive Immune Complex Formation Interferes with
Antibody-Mediated Depletion
A hallmark of chronic LCMV infection is the induction of a
vigorous B cell response resulting in hypergammaglobulinemia
for a prolonged period of time (Hunziker et al., 2003). Thus, we
sought out to determine whether this vigorous B cell response
contributes to the observed resistance to antibody-mediated
depletion. To address this issue, we took advantage of the IgHEL
tg mouse model (MD4), in which B cells express a transgene en-
coding an immunoglobulin (Ig) specific for hen egg lysozyme
(HEL) (Mason et al., 1992). Due to allelic exclusion, >98% of all
peripheral B cells in IgHEL tg mice are specific for HEL (Silveira
et al., 2002). This model allowed us to directly investigate the
effect of a reduced anti-viral B cell response on antibody-medi-
ated depletion. Wild-type (WT) and IgHEL tg mice showed
comparable viral titers on day 28 post LCMV clone-13 infection
(Figure 4A). As expected, LCMV clone-13-infected IgHEL tg
mice showed reduced LCMV-specific antibody titers (30-fold)
compared to infected WT controls (Figures 4B and 4C). How-
ever, LCMV clone-13-infected IgHEL tg mice showed some het-
erogeneity regarding LCMV-specific antibody titers (Figure 4B).
LCMV clone-13 infection of IgHEL tg mice resulted in hypergam-
maglobulinemia compared to naive controls with a 3- to 4-fold
increase in total IgG (Figure 4D). However, total IgG titers in
LCMV clone-13-infected IgHEL tg mice were lower compared
to infected WT controls, which showed a 10-fold increase in
total IgG.
Persistent LCMV infection has been shown to induce ICs
containing the major structural LCMV proteins (Buchmeier
and Oldstone, 1978; Oldstone et al., 1980). As we observed
high viral load, as well as high antibody titers in LCMV clone-
13 infected WT mice, we hypothesized that chronic LCMV
infection results in excessive IC formation and thus impairs370 Immunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc.FcgR-mediated clearance of opsonized target cells. We thus
analyzed the serum for the presence of circulating immune
complexes (CIC). In accordance with our hypothesis, we de-
tected lower amounts of CIC in the serum of LCMV clone-13-
infected IgHEL tg mice compared to infected WT controls (Fig-
ure 4E). CIC showed a comparable IgG subclass composition
as total serum IgG (Figure S3). We thus compared the effi-
ciency of depleting CD4+ T cells in WT and IgHEL tg mice in
the presence or absence of a chronic LCMV clone-13 infection.
Antibody-mediated depletion of CD4+ T cells was more effi-
cient in chronically infected IgHEL tg mice compared to WT in-
fected mice ranging from 33%–98% versus 10%, whereas
no difference in the depletion efficiency of CD4+ T cells be-
tween naive WT and IgHEL tg mice was observed (Figures 4F
and 4G). The majority of LCMV clone-13 infected IgHEL tg
mice showed a CD4+ T cell depletion efficiency of >90%,
whereas some IgHEL tg mice, which tended to have higher
LCMV-specific antibody titers showed lower depletion effi-
ciencies (Figure 4H). However, no correlation was observed be-
tween total IgG titers and CD4+ depletion (Figure S4). As PECs
from chronically infected mice did not show intrinsic defects in
FcgR-dependent phagocytosis (Figure 3C), we investigated
whether pre-treatment of PECs with serum of LCMV clone-
13-infected mice could inhibit FcgR-mediated phagocytosis
in vitro and thus mimic the impaired depletion efficiency
observed in vivo. Indeed, serum of LCMV clone-13-infected
mice efficiently inhibited FcgR-mediated phagocytosis in vitro
(Figure S5). Together, these data suggest that excessive forma-
tion of ICs during chronic LCMV clone-13 infection impairs the
antibody-mediated clearance of opsonized target cells by
competition for available FcgRs.
We next sought to confirm the results obtained in IgHEL tg
mice using another chronic LCMV infection model lacking
LCMV-specific antibodies, as well as virus-specific CD4+
T cells due to transient depletion of CD4+ T cells prior to infec-
tion (GK LCMV clone-13) (Matloubian et al., 1994; Zajac et al.,
1998). We compared the CD4+ T cell depletion efficiency in
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Figure 3. Phagocytes of Naive and LCMV Clone-13-Infected Mice Show Comparable Phagocytic Activity In Vitro
(A) On day 1, micewere injected i.p. with 100 mg anti-NK1.1, 200 ml clodronate liposomes or left untreated.Micewere then injected twicewith 0.5mg anti-CD4 and
sacrificed on day 2. Number of splenic CD4+ T cells on day 2 post anti-CD4 treatment start (n = 4–5 mice per group).
(B) Purified CD11b+ splenocytes and (C) peritoneal exudate cells of naive and LCMV clone-13-infected mice (d35 p.i.) were incubated with fluorescently labeled
unopsonized or opsonized erythrocytes in the presence or absence of FcgRII/III-blocking antibody 2.4G2. Phagocytic activity was analyzed by flow cytometry
(n = 3 replicates per group). Data (mean ± SEM) from one representative experiment of two are shown. Unpaired two-tailed Student’s t test was used. *p < 0.05,
***p < 0.0001. ns indicates not significant. See also Figure S2.LCMV clone-13 and GK LCMV clone-13-infected mice 4 weeks
post infection, as well as in age-matched, uninfected controls
upon two intraperitoneal injections of anti-CD4. At this time
point post infection, GK LCMV clone-13-infected mice already
showed a reconstitution of their CD4+ T cell compartment and
high viral loads (Figure 5A). We observed high titers of LCMV-
specific antibodies (Figures 5B and 5C) and a 10-fold increase
in total IgG in the serum of LCMV clone-13-infected mice (Fig-
ure 5D). In contrast, GK LCMV clone-13-infected mice lacking
virus-specific CD4+ T cells did not mount a B cell response
against LCMV and showed no increase in total serum IgG.
We detected higher amounts of CIC in the serum of LCMV
clone-13-infected mice compared to GK LCMV clone-13-in-
fected mice and uninfected controls (Figure 5E). In accordance
with the absence of LCMV-specific antibodies, GK LCMV
clone-13-infected mice showed no increase in CIC compared
to naive controls. Consistent with our hypothesis, the suscepti-
bility of CD4+ T cells in GK LCMV clone-13-infected mice to
antibody-mediated depletion was strikingly higher compared
to LCMV clone-13-infected mice (>98% versus <10%) and
comparable to naive controls (>98%) (Figure 5F). These data
further support our hypothesis that during chronic LCMV
clone-13 infection a vigorous B cell response leads to exces-
sive formation of ICs and thus impairs FcgR-mediated clear-
ance of opsonized target cells.
Hypergammaglobulinemia Alone Does Not Interfere
with FcgR-Mediated Clearance of Opsonized Cells
The above depletion experiments in IgHEL tg mice showed that
reduced B cell responses during chronic LCMV clone-13 infec-
tion allowed efficient antibody-mediated depletion of CD4+
T cells. However, these experiments did not address the ques-
tion whether hypergammaglobulinemia in general could interfere
with antibody-mediated depletion or antigen-specific antibodies
and the presence of cognate antigen and the subsequent forma-
tion of ICs are required during chronic LCMV clone-13 infection.
To test whether hypergammaglobulinemia in general interferes
with antibody-mediated depletion, we transferred high amountsof purified mouse IgG (polyclonal or monoclonal origin) intrave-
nously (i.v.) to naive C57/BL6 mice. Compared to IgG of chroni-
cally infected mice, transferred polyclonal IgG showed only
slight differences in its subclass composition but 2-fold lower
amounts of sialylic acid in the total IgG glycan preparation, which
includes Fc- and Fab-associated glycans (Figures S6A and
S6B). Sialylation of the Fc domain has been shown to reduce
the affinity to FcgRs, suggesting that the transferred polyclonal
IgG might have higher affinity to FcgRs compared to IgG of
chronically infectedmice (Kaneko et al., 2006). High-dosemono-
clonal or polyclonal IgG transfer into naive mice resulted in an
increase in serum IgG concentrations (8 fold) comparable to
chronically LCMV clone-13 infected controls (Figure 5G). We
next performed an in vivo depletion assay as described above
using anti-CD4 coated and uncoated purified CD4+ T cells
from naive mice. High-dose IgG recipients efficiently cleared
anti-CD4 coated CD4+ T cells despite high concentrations of
serum IgG, whereas LCMV clone-13-infectedmice failed to elim-
inate opsonized target cells (Figure 5H). Hypergammaglobuline-
mia induced by transfer of purified mouse IgG resulting in total
IgG concentrations comparable to LCMV clone-13-infected
mice did thus not interfere with antibody-mediated depletion,
whereas serum of chronically infected mice containing ICs and
only 4–5 mg IgG efficiently inhibited antibody-mediated deple-
tion (Figure S7).
Chronic LCMV Infection Interferes with the Ability of
Different Antibodies to Deplete Various Lymphocyte
Subsets
We next sought out to determine whether the observed resis-
tance to antibody-mediated depletion during chronic LCMV
clone-13 infection is only restricted to CD4+ T cells and the anti-
body used to deplete CD4+ T cells or whether it represents a
general defect in antibody-mediated depletion. Therefore, we
investigated the depletion efficiency of additional antibodies
directed against various surface molecules in naı¨ve, as well as
LCMV clone-13-infected, mice. We observed severely impaired
depletion efficiency using antibodies targeting CD8a and CD25Immunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc. 371
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Figure 4. CD4+ T Cells Can Be Efficiently Depleted in Chronic LCMV Clone-13 Infected IgHEL tg Mice
(A–H) WT and IgHEL tg C57/BL6 mice were infected with LCMV clone-13. (A) Viral titers, (B and C) LCMV- specific IgG titers, (D) total IgG, and (E) circulating
immune complexes (CIC) in serumwere analyzed on day 28 p.i. The black dotted lines indicate the lower level of detection. (F andG)Micewere then injected twice
with 0.5 mg anti-CD4 depleting antibody. CD4+ T cell depletion in the peripheral blood was analyzed 2 days after treatment start. (F) CD4+ depletion efficiency. (G)
Representative flow plots of CD4+ T cells in the peripheral blood of WT B6 and IgHEL tg mice before and 2 days post treatment start. Numbers represent
frequency of CD4+ T cells as percentage of PBMC. (H) Linear regression and Pearson’s correlation were used to show the association between CD4+ depletion
efficiency and LCMV-specific antibody titers in chronically infected IgHEL tg mice. R2 and p value for Pearson’s correlation are shown. Data (mean ± SEM)
from one representative experiment of at least two (n = 3-10 mice per group) are shown. Unpaired two-tailed Student’s t test was used. *p < 0.05, **p < 0.005,
***p% 0.001. ns indicates not significant. See also Figures S3–S5.during chronic LCMV clone-13 infection compared to naive con-
trols (Table S1). These data further support our hypothesis that
chronic LCMV clone-13 infection interferes with FcgR-mediated
antibody effector functions by excessive formation of ICs and
subsequent competition for available FcgRs. Interestingly, an
antibody directed against CD90.2 (30H12) was able to deplete
T cells in naive and LCMV clone-13-infected mice to a com-
parable extent demonstrating that the observed interference
with FcgR-mediated antibody effector functions during chronic
LCMV clone-13 infection can be overcome.372 Immunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc.Rituximab-Mediated B Cell Depletion Is Severely
Impaired in Chronically LCMV-Infected Mice
Rituximab, a humanized anti-hCD20 mAb, is widely used for
treatment of non-Hodgkin’s lymphoma and autoimmune dis-
eases (Browning, 2006; Cheson and Leonard, 2008; Edwards
et al., 2004). However, a number of patients fail to respond to
treatment due to mostly unknown reasons (Alduaij and Illidge,
2011). To determine whether chronic LCMV infection also inter-
feres with the depletion efficiency of rituximab, we assessed the
effect of chronic LCMV clone-13 infection on the depletion
GK
 LC
MV
 Cl
13
LC
MV
 Cl
13
101
102
103
104
105
se
ru
m
 
vir
al
 
tite
r 
(pf
u/
m
l)
*
8 10 12 14 16 18 20
0.0
0.5
1.0
1.5
2.0
2.5
3.0
serum dilution (log 2)
LC
M
V-
sp
ec
ific
 Ig
G
 (O
D 4
90
)
naive
LCMV Cl13
GK LCMV Cl13
na
ive
GK
 LC
MV
 Cl
13
LC
MV
 Cl
13
101
102
103
104
105
106
LC
M
V 
sp
ec
ific
 
Ig
G 
tite
r
**
**
ns
na
ive
GK
 LC
MV
 Cl
13
LC
MV
 Cl
13
0
2
4
6
8
10
12
to
ta
l s
er
u
m
 
Ig
G 
(m
g/
m
l) ***
ns
***
na
ive
GK
 LC
MV
 Cl
13
LC
MV
 Cl
13
0.0
0.2
0.4
0.6
0.8
1.0
CI
C 
(O
D
49
0)
***
***
ns
na
ive
GK
 LC
MV
 Cl
13
LC
MV
 Cl
13
0
20
40
60
80
100
CD
4+
 
de
ple
tio
n
 (%
)
***
ns ***
-
-
-
po
lyc
lon
al
m
on
oc
lon
al
105
106
107
to
ta
l Ig
G 
tite
r
***
**
**
LCMV Cl13
naive mice transferred 
with indicated IgG
-
-
-
po
lyc
lon
al
m
on
oc
lon
al
0
20
40
60
80
100
D
ep
let
io
n
 e
ffi
cie
n
cy
 
(%
)
***
ns
ns
LCMV Cl13
naive mice transferred 
with indicated IgG
A B C
D E F
G H
Figure 5. CD4+ T Cells Can Be Efficiently Depleted in LCMV Clone-13-Infected Mice Lacking LCMV-Specific Antibodies
(A–F) Mice were depleted of CD4+ T cells (GK) prior to LCMV clone-13 infection. (A) Viral titers, (B and C) LCMV specific IgG titers, (D) total IgG, and (E) circulating
immune complexes (CIC) in serum were analyzed on day 28 p.i. The black dotted lines indicate the lower level of detection. (F) Mice were then injected twice with
0.5 mg anti-CD4 depleting antibody. CD4+ T cell depletion in the peripheral blood was analyzed 2 days after treatment start.
(G and H) Mice were infected with LCMV clone-13 28 days prior to analysis. Naive mice received 10 mg polyclonal IgG, monoclonal IgG, or PBS 18 hr prior
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Depletion efficiency of anti-CD4 coated T cells. Data (mean ± SEM) from one representative experiment of two (n = 3–5mice per group) are shown. Unpaired two-
tailed Student’s t test was used. *p < 0.05, **p < 0.005, ***p% 0.001. ns indicates not significant. See also Figures S6 and S7.efficiency of rituximab in a hCD20 tg mouse model expressing
hCD20 specifically on mature B cells (Ahuja et al., 2007). We
treated chronically infected hCD20 tg mice (4 weeks post infec-
tion) and age-matched naive controls with 1 mg rituximab i.p. on
days 0, 2, and 4. Treatment of naive hCD20 tg mice with rituxi-
mab resulted in efficient depletion of (CD19+ B220+) B cells in
the circulation (>95%) within a week, whereas rituximab treat-ment of LCMV clone-13 infected animals showed a lower deple-
tion efficiency (Figures 6A and 6B). The B cell depletion efficiency
in chronically infected mice varied between individual mice but
did not exceed 15% on average. Similar results were obtained
when hCD20 tgmicewere treatedwith amurine anti-hCD20 anti-
body, 2H7, recognizing an epitope similar to that of rituximab
(Table S1). To examine whether the observed resistance of BImmunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc. 373
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Figure 6. Rituximab-Mediated B Cell Depletion Is Severely Impaired
in Chronically LCMV Clone-13-Infected Mice
(A–C) Naive and LCMV clone-13-infected hCD20 tg mice (d28 p.i.) were in-
jected three times with 1 mg rituximab. (A) Representative flow plots of B cells
in the peripheral blood of naive, LCMV clone-13-infected and GK LCMV clone-
13-infected mice prior and 7 days post rituximab treatment. Numbers repre-
sent frequency of B cells as a percentage of PBMC. (B) B cell depletion and (C)
rituximab concentrations in the peripheral blood on day 7 post treatment start.
(D) Representative histogram (left panel) and statistics (right panel) of surface
bound rituximab on B cells from naive and LCMV clone-13-infected mice 3 hr
post treatment start. Data (mean ± SEM) from one representative experiment
of three (n = 3–5 mice per group) are shown. Unpaired two-tailed Student’s t
test was used. ***p% 0.001. ns indicates not significant. See also Table S1.cells to depletion was due to reduced half-life of the injected rit-
uximab in chronically infected mice, we measured the serum
concentrations of intact, bio-active rituximab (able to bind
hCD20) using an anti-idiotype ELISA. We detected no differ-
ences in serum concentrations of rituximab between naive
mice showing efficient B cell depletion and chronically LCMV
clone-13-infected mice with severely impaired B cell depletion
(Figure 6C). In vitro activation of human B cells with agonistic374 Immunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc.anti-CD40 has shown to result in rapid and dramatic downregu-
lation of hCD20 (Anolik et al., 2003). In addition, previous studies
showed rituximab-mediated downregulation of hCD20 on the
surface of B cells from hCD20 tg mice, as well as patients with
Chronic Lymphatic Leukemia or Mantle Cell Lymphoma (Jilani
et al., 2003; Li et al., 2007). To examine whether B cells from
naive and chronically infected hCD20 tg mice differentially
downregulated surface expression of hCD20 in response to rit-
uximab, we stained for rituximab on surface of B cells 3 hr
post treatment start. We detected comparable amounts of ritux-
imab bound to the surface of B cells from naive and chronically
infectedmice (Figure 6D), suggesting that the impaired depletion
of B cells in chronically infected mice is likely not due to differ-
ences in binding of rituximab.
FcgR-Dependent Agonistic Anti-CD40 Fails to Activate
DCs in LCMV Clone-13-Infected Mice
To further demonstrate that excessive IC formation during
chronic LCMV infection can interfere with various FcgR-medi-
ated antibody effector functions, we investigated the in vivo
activity of an agonistic anti-CD40 antibody. Signaling through
CD40, an important costimulatory member of the TNFR family,
results in the activation and licensing of DCs allowing them to
efficiently stimulate T cell responses (Bennett et al., 1998;
Schoenberger et al., 1998). Agonistic anti-CD40 antibodies
have been shown to require inhibitory FcgRs but not FcgR
signaling components for their in vivo activity suggesting that
inhibitory FcgRs due to their wide cellular distribution and high
expression serve as a scaffold to allow cross-linking of CD40
(Li and Ravetch, 2011, 2013). We treated naive and LCMV
clone-13-infected mice with 80 mg agonistic anti-CD40 antibody
(FGK45) and analyzed the activation of DCs in the spleen.
Lymphoid CD8a+ DCs in naive mice were efficiently activated
by anti-CD40 and upregulated the costimulatory molecules
CD80 and CD86 (Figures 7A and 7B). In contrast, lymphoid
CD8a+ DCs in LCMV clone-13-infected mice did not upregulate
CD80 or CD86 in response to anti-CD40 treatment. We obtained
comparable results analyzing myeloid CD11b+ DCs (Figure 7C)
demonstrating that the observed failure of the agonistic anti-
CD40 to activate DCs is not specific to a distinct DC subset.
However, consistent with the data from our depletion experi-
ments, lymphoid and myeloid DCs could be efficiently activated
in LCMV clone-13-infected mice lacking LCMV-specific anti-
bodies due to CD4+ depletion prior to infection (Figures 7D and
7E). These data suggest that excessive IC formation during
chronic LCMV infection can interfere with various FcgR-medi-
ated processes by competition for available FcgRs.
DISCUSSION
In this report, we show for the first time that chronic LCMV
clone-13 infection interferes with FcgR-mediated antibody
effector functions. We observed a striking resistance to anti-
body-mediated depletion in mice chronically infected with
LCMV clone-13, which was cell type independent as antibodies
to different lymphocyte subsets failed to efficiently deplete
their targets. We demonstrated that this resistance was not
due to target cell intrinsic mechanisms but clearly linked to
excessive IC formation as a result of a vigorous B cell response.
A B
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Figure 7. Agonistic Anti-CD40 Fails to Activate DCs in LCMV Clone-13-Infected Mice
(A–C) Naive and LCMV clone-13-infected mice (d21 p.i.) were injected i.p. with 80 mg agonistic anti-CD40 and splenic DC activation was analyzed after 24 hr. (A)
Representative flow plots of splenic CD11chi DCs. Numbers represent frequency of lymphoid CD8a+ and myeloid CD11b+ DCs as percentage of CD11c+ DCs.
Representative histograms of CD80 and CD86 expression on lymphoid CD8a+ DCs in untreated (gray) or anti-CD40 treated (red) mice. (B) Expression of CD80
and CD86 on lymphoid CD8a+ DCs. (C) Expression of CD80 and CD86 on myeloid CD11b+ DCs.
(D and E) Expression of CD80 and CD86 on (D) lymphoid DCs and (E) myeloid DCs upon anti-CD40 injection into mice depleted of CD4+ T cells prior to LCMV
infection (GK LCMV Cl13). Data (mean ± SEM) from one representative experiment (n = 3 mice per group) are shown. Unpaired two-tailed Student’s t test was
used. *p < 0.05, **p < 0.005. ns indicates not significant.As antibody-mediated depletion of cells in vivo is thought to be
mainly FcgR-mediated (Gong et al., 2005; Uchida et al., 2004)
and ICs are considered to be the main ligands for the relevant
FcgRs (Nimmerjahn and Ravetch, 2008), we propose that during
chronic LCMV clone-13 infection high amounts of ICs occupy
FcgRs and thus restrict FcgR-mediated antibody effector func-
tions. This hypothesis was further supported by the lack of DC
activation after administration of a FcgR-dependent agonistic
anti-CD40 antibody to mice chronically infected with LCMV.
Transfer of polyclonal mouse IgG showed that hypergamma-
globulinemia alone at concentrations observed in chronically in-
fected mice is not sufficient to impair the antibody-mediated
depletion of cells. However, due to differences in the subclass
composition and glycosylation profile of the transferred IgG
and the IgG in chronically infected mice, we cannot exclude
the possibility that monomeric IgG of LCMV clone-13-infected
mice might partially contribute to the observed interference
with FcgR-mediated antibody effector functions in vivo.
Rituximab, as well as other therapeutic antibodies, have
improved survival rates of cancer patients; however, a number
of patients fail to respond to treatment due to mostly unknown
reasons. FcgR polymorphisms and increased expression of
CD47 on cancer cells have been implicated to predict clinicaloutcome (Majeti et al., 2009; Musolino et al., 2008). Chronic viral
infections, such as HBV, HCV, and HIV, have been linked to can-
cer development and are estimated to account for up to 18% of
global cancer burden (Parkin, 2006). However, no study has yet
investigated the effect of a chronic viral infection on ADCC in
detail despite its suggested impact on viral control in several
studies (DiLillo et al., 2014; Hessell et al., 2007). It is important
to point out that we only observed impaired FcgR-mediated pro-
cesses in our in vivo but not in vitro experiments as ICs probably
occupy FcgRs in vivo and thus restrict antibody effector func-
tions such as ADCC. Current assays to measure ADCC activity
are routinely performed in vitro and might thus not be able to
reflect the in vivo ADCC activity properly.
Reduced efficacy of B cell depletion was first reported in the
MRL mouse model of systemic lupus erythematosus (Ahuja
et al., 2007). Consistent with our data, a follow-up study demon-
strated for the first time that the IgG fraction of lupus serum con-
taining autoantibodies and presumably ICs interfere with anti-
body-mediated depletion in vivo (Ahuja et al., 2011). Like many
chronic viral infections such as HIV, HBV, and HCV (Kawamoto
et al., 1993; Zandman-Goddard and Shoenfeld, 2002), persistent
LCMV infection has been shown to induce hypergammaglobuli-
nemia for prolonged periods of time. In addition, chronic HBVImmunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc. 375
and HCV infections have also been reported to be accompanied
by ICs (Tsai et al., 1995).
In addition, our results demonstrate that the in vivoactivity of an
agonistic anti-CD40 antibody, which has been shown to require
inhibitory FcgRs, but not FcgR signaling components (Li and
Ravetch, 2013), is severely compromised during chronic LCMV
infection. This suggests that excessive IC formation during
chronic infections and subsequent competition for FcgR-binding
is not only impairing FcgR-mediated cellular depletion but also
other FcgR-mediated processes in vivo, ranging from activation
of innate cells to regulating immune responses and mediating
ADCC (Nimmerjahn and Ravetch, 2008; Pincetic et al., 2014).
Uptake of ICs by DCs through activating FcgRs does not only
result in efficient processing and presentation of antigens on
MHC-I and MHC-II molecules but also influences the maturation
of DCs, thereby shaping the cellular immune response (Kalergis
and Ravetch, 2002; Regnault et al., 1999). Recent studies have
shown that even broadly neutralizing antibodies against influ-
enza virus and HIV require FcgR interactions to mediate their
protective activity in vivo (Bournazos et al., 2014; DiLillo et al.,
2014; Hessell et al., 2007). NK cells were implicated to play a
crucial role for protection, because they are able to lyse virus-
infected cells coated with antibodies by ADCC, an FcgR-de-
pendent process likely to be also impaired by excessive IC
formation, which could potentially contribute to viral persistence.
In addition, because FcgR-mediated phagocytosis has been
shown to contribute to clearance ofmultiple pathogens (Kiriman-
jeswara et al., 2005; Zhang et al., 2005), the reduced availability
of FcgRs during chronic infections might also favor and/or pro-
long bacterial superinfections. Excessive IC formation might
thus contribute in multiple ways to immune dysregulation
observed during chronic infections.
Our results might also have important implications for thera-
peutic interventions aimed at improving immune responses
during chronic viral infections and cancer, becausemultiple ther-
apeutic strategies have shown to require engagement of FcgRs.
The therapeutic efficacy of anti-CTLA-4, which has been suc-
cessfully used to treat melanoma, appears to depend on FcgR
interactions to deplete regulatory T cells and enhance antitumor
T cell responses in mice (Simpson et al., 2013). In addition, a
recent report showed that interleukin-7 (IL-7), a cytokine critical
for immune development and homeostasis, applied as IL-7-anti-
IL7 mAb complex, has increased potency by extending its half-
life due to binding the neonatal FcgR (Martin et al., 2013).
Our results underline the need for more efficient antibody-
mediated therapies to overcome the obstacle of high IC concen-
trations during chronic infections. Interestingly, depletion of
T cells using an anti-CD90 antibody was not impaired during
chronic LCMV clone-13 infection. One potential explanation
might be the abundance of CD90 on the surface of T cells (Haer-
yfar and Hoskin, 2004). Upon treatment, the density of bound
anti-CD90 antibody on the surface of T cells might be above
the critical threshold set by competing ICs to allow efficient
phagocytosis. However, the exact mechanism by which this
antibody exerts its function in the presence of high IC is still un-
der investigation.
A previous study showed that persistent administration of high
doses of anti-hCD20 results in successful B cell depletion inMRL
mice, demonstrating as well the general feasibility to deplete376 Immunity 42, 367–378, February 17, 2015 ª2015 Elsevier Inc.cells in the presence of high amounts of ICs (Ahuja et al.,
2007). A more cost-effective and promising strategy might be
the use of mAbs, designed to improve the delivered effector
functions by enhancing their affinity for FcgRs (Alduaij and Il-
lidge, 2011). Increased affinity for FcgRs might be especially
beneficial in situations when therapeutic antibodies are com-
peting with endogenous ICs for binding to FcgRs.
It has been recently shown that blocking CD47 synergizes with
rituximab to promote phagocytosis of NHL (Chao et al., 2010;
Jaiswal et al., 2009). In our study, we detected no differences
regarding the expression of CD47 in naive and LCMV clone-
13-infected mice. However, it is possible that in the presence
of excessive ICs and thus reduced availability of FcgRs,
signaling via basal CD47 expression is sufficient to outweigh
the limited FcgR engagement and therefore prevent phagocy-
tosis of target cells.
In summary, our study provides insight into a mechanism by
which chronic viral infections can interfere with humoral immu-
nity. While T cell dysfunction and its impact on viral control
have been well studied, less is known about dysfunctions of
the humoral immune system during chronic infections. Our study
shows that chronic LCMV infection interferes with FcgR-medi-
ated antibody effector functions by excessive IC formation.
This might represent an additional mechanism besides T cell
exhaustion contributing to viral persistence. Our study also has
important implications for the treatment of autoimmune diseases
and cancer with depleting antibodies relying on the engagement
of FcgRs.
EXPERIMENTAL PROCEDURES
Mice and Viruses
Themouse and virus strains used and procedures are described in the Supple-
mental Experimental Procedures. Animals were housed at the Emory Univer-
sity School of Medicine animal facility, and experiments were performed in
accordance with approved IACUC protocols.
Flow Cytometry and Antibodies
Lymphocytes were isolated from spleen and blood as described previously
(Barber et al., 2006). Cells were stained with fluorochrome-conjugated anti-
bodies (purchased from BioLegend). The polyclonal anti-human IgG Fcg frag-
ment-specific antibody used to detect bound rituximab on the surface of B
cells was purchased from eBioscience. Dead cells were stained using Live/
Dead Fixable Aqua Dead Cell Stain (Invitrogen). After staining, cells were fixed
in 1% paraformaldeyde and acquired using FACS Calibur or Canto II flow cy-
tometer (BD Biosciences). Data were analyzed using FlowJo (Treestar).
Depletion of Lymphocytes and Phagocytic Cells
Detailed procedures are described in the Supplemental Experimental
Procedures.
DC Activation
Mice were injected i.p. with 80 mg of agonistic anti-CD40 antibody (FGK45;
BioXCell) 24 hr prior to analysis.
ELISA
Detailed procedures are described in the Supplemental Experimental
Procedures.
In Vitro Phagocytosis Assay
Peritoneal exudate cells (PECs) were obtained by peritoneal lavage of naive
and LCMV clone-13 infected C57BL/6 mice 3 days after injection of 3% thio-
glycollate broth. Splenic macrophages/monocytes were purified from spleens
of naive and LCMV clone-13-infected mice using CD11b+ magnetic beads
(Miltenyi). The analysis of the phagocytic capacity of PEC and splenic macro-
phages/monocytes in vitro was carried out using flow cytometry as des-
cribed earlier (Shashidharamurthy et al., 2008; Zhang et al., 2005). Briefly,
sheep erythrocytes were coated with dinitrophenyl (DNP), opsonized with
Alexa488-labeled rabbit anti-DNP antibodies, and incubated at a ratio of
1:50 (macrophages to erythrocytes) in the presence or absence of FcgRII/III-
blocking antibody (2.4G2; BD PharMingen).
In Vivo Depletion Assay
This assay was performed similarly as a previously described in vivo cytotox-
icity assay (Barber et al., 2003). CD4+ T cells from spleens of infected and un-
infected C57BL/6mice were purified to >90% purity by depletion of non-CD4+
T cells usingmagnetic beads (Miltenyi), followed by labeling with different con-
centrations of CellTrace Violet and CFSE (both from Invitrogen), and coating
with anti-CD4 antibody (GK1.5; BioExpress). A mixture of cells containing
equal proportions of anti-CD4 coated and uncoated cells from uninfected,
LCMV Arm-immune and LCMV clone-13-infected mice was then transfer by
i.v. injection to uninfected, LCMV Arm-immune and LCMV clone-13-infected
C57/BL6 mice. Mice were sacrificed 3–4 hr post transfer and in vivo phago-
cytic activity was determined by flow cytometric analysis of fluorescently
labeled CD3+ CD8 splenocytes.
Immunoglobulin Transfer
Mice were injected i.v. with 10 mg mouse IgG in a total volume of 500 ml PBS.
Polyclonal mouse IgG (Kunming strain) was purchased from Jackson Immu-
noResearch. Monoclonal mouse IgG (isotype IgG2b) was purified from culture
supernatants of the hybridoma 2H7, a kind gift of Edward Clark (University of
Washington), as described previously (Ahuja et al., 2007).
Glycan Analysis
Procedures are described in the Supplemental Experimental Procedures.
Statistical Analysis
All data were analyzed using Prism 5.0 (GraphPad).
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2015.01.009.
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